


Ask a doctor about a prescription for HEXVIX 85 mg POWDER AND SOLVENT FOR INTRAVESICAL SOLUTION
Package Leaflet: Information for the Patient
HEXVIX 85 mg powder and solvent for intravesical solution
Hexaminolevulinate
Read this package leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the package leaflet:
This medicine is for diagnostic use only.
This medicine is used to help detect bladder cancer. It is given before your doctor uses a special device called a "cystoscope" that allows them to visualize the inside of your bladder. A cystoscope helps to visualize possible tumors and thus to eliminate abnormal cells, which glow in blue light after administration of Hexvix.
Do not use Hexvix:
Warnings and precautions:
Consult your doctor or nurse before you start using Hexvix.
These circumstances may cause local reactions in your bladder, which may make it difficult for your doctor to interpret what they see during the examination.
Other medicines and Hexvix:
Tell your doctor if you are taking or have recently taken other medicines, including those bought without a prescription.
Fertility, pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Driving and using machines
Ask your doctor for advice about driving and using machines after taking Hexvix.
Hexvix must be prepared and administered by qualified personnel. Hexvix is usually administered in a hospital or clinic.
Your doctor will give it to you in the following way:
If you use more Hexvix than you should
No side effects are expected to occur if the dwell time of Hexvix in the bladder is increased above 60 minutes or if the amount of Hexvix used is increased. If you are concerned about this, consult your doctor or nurse.
Like all medicines, Hexvix can cause side effects, although not everybody gets them. There is a risk of possible side effects related to the technique (cystoscopy) used to examine your bladder. Generally, the use of Hexvix as a complementary method to standard cystoscopy for a more accurate diagnosis of bladder cancer is well tolerated. If side effects occur, they will be those typically associated with the examination technique, usually not serious or prolonged. The following side effects may occur after the examination procedure using this medicine:
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Frequency not known(cannot be estimated from the available data):
Reporting of side effects
If you experience any side effects, consult your doctor, even if they are not listed in this package leaflet. You can also report side effects directly through the Spanish Medicines Agency's website. www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the outer packaging. The expiry date refers to the last day of the month.
Powder and solvent: the product does not require special storage conditions.
Solution (after mixing): store between 2°C and 8°C (in the refrigerator) for a maximum period of 2 hours.
Hospital staff must ensure that the product is stored and disposed of properly and that it is not used after the expiry date printed on the outer packaging.
Marketing authorization holder and manufacturer:
Photocure ASA
Hoffsveien 4
NO-0275 Oslo,
Norway
You can ask for more information about this medicine by contacting the marketing authorization holder.
This medicine has been authorized with the trade name Hexvix in the following European Economic Area member states and in the United Kingdom (Northern Ireland):Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Iceland, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Slovenia, Spain, Sweden, and the United Kingdom (Northern Ireland).
Date of last revision of this package leaflet:January 2022
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es
This information is intended only for healthcare professionals:
Handling instructions
Hexaminolevulinate may cause sensitization through skin contact.
All steps must be performed with sterile material and under aseptic conditions.
Reconstitution procedure: Hexvix powder and solvent for Hexvix in pre-filled syringe
|
|
|
|
|
|
|
|
|
|
Hexvix is now reconstituted and ready to use. The appearance of the reconstituted solution is a clear or slightly opalescent solution, and colorless to pale yellow.
Add two hours to the current time and write the resulting expiration time and date on the syringe label
This product is for single use only. Any remaining product should be discarded. No special requirements for disposal.
It has been demonstrated that the solution maintains its chemical and physical stability for a period of 2 hours at 2°C - 8°C. From a microbiological point of view, the product should be used immediately. If not, the storage times and conditions before use are the responsibility of the user and should not normally exceed 2 hours at 2°C - 8°C.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for HEXVIX 85 mg POWDER AND SOLVENT FOR INTRAVESICAL SOLUTION – subject to medical assessment and local rules.